Effectiveness and safety of nirmatrelvir+ritonavir in COVID-19. NiRCoV Study: Correspondence H. Daungsupawong; V. Wiwanitkit;

Immunogenicity of BNT162b2 vaccine after two and three doses: Correspondence H. Daungsupawong; V. Wiwanitkit;